Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Pulmonary hypertension: Clinical parameters of a difficult case in pregnancy.

Calhoun BC.

Linacre Q. 2017 Aug;84(3):243-247. doi: 10.1080/00243639.2016.1173812. Epub 2017 Aug 22.

PMID:
28912617
2.

Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies.

Goldberg AB, Mazur W, Kalra DK.

Cardiovasc Diagn Ther. 2017 Aug;7(4):405-417. doi: 10.21037/cdt.2017.04.11. Review.

3.

Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy.

Rammo R, Robin A, John J, Pabaney A, Varelas P, Kole M.

Surg Neurol Int. 2017 Aug 1;8:161. doi: 10.4103/sni.sni_65_17. eCollection 2017.

4.

Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges.

Lajoie AC, Bonnet S, Provencher S.

Pulm Circ. 2017 Apr-Jun;7(2):312-325. doi: 10.1177/2045893217710639. Epub 2017 May 30.

5.

A systematic review of transition studies of pulmonary arterial hypertension specific medications.

Sofer A, Ryan MJ, Tedford RJ, Wirth JA, Fares WH.

Pulm Circ. 2017 Apr-Jun;7(2):326-338. doi: 10.1177/2045893217706357. Epub 2017 May 12.

6.

Identifying "super responders" in pulmonary arterial hypertension.

Halliday SJ, Hemnes AR.

Pulm Circ. 2017 Apr-Jun;7(2):300-311. doi: 10.1177/2045893217697708. Epub 2017 May 30.

7.

Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.

Gao XF, Zhang JJ, Jiang XM, Ge Z, Wang ZM, Li B, Mao WX, Chen SL.

Patient Prefer Adherence. 2017 May 8;11:871-885. doi: 10.2147/PPA.S133288. eCollection 2017.

8.

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.

Lian TY, Jiang X, Jing ZC.

Drug Des Devel Ther. 2017 Apr 13;11:1195-1207. doi: 10.2147/DDDT.S117277. eCollection 2017. Review.

9.

Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Badlam JB, Bull TM.

Ther Adv Chronic Dis. 2017 Feb;8(2-3):47-64. doi: 10.1177/2040622317693218. Epub 2017 Mar 1. Review.

10.

Pulmonary Hypertension.

Hoeper MM, Ghofrani HA, Grünig E, Klose H, Olschewski H, Rosenkranz S.

Dtsch Arztebl Int. 2017 Feb 3;114(5):73-84. doi: 10.3238/arztebl.2017.0073.

11.

An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.

Oudiz R, Agarwal M, Rischard F, De Marco T.

Pulm Circ. 2016 Dec;6(4):532-538. doi: 10.1086/688711.

12.

Recent advances in the management of pulmonary arterial hypertension.

Tsai H, Sung YK, de Jesus Perez V.

F1000Res. 2016 Nov 24;5:2755. doi: 10.12688/f1000research.9739.1. eCollection 2016. Review.

13.

A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy.

Ataya A, Cope J, Alnuaimat H.

J Clin Med. 2016 Dec 6;5(12). pii: E114. Review.

14.

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.

Hardin EA, Chin KM.

Drug Des Devel Ther. 2016 Nov 15;10:3747-3754. eCollection 2016. Review.

15.

Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.

Maron BA, Galiè N.

JAMA Cardiol. 2016 Dec 1;1(9):1056-1065. doi: 10.1001/jamacardio.2016.4471.

PMID:
27851839
16.

Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding.

Hu J, Sharifi-Sanjani M, Tofovic SP.

J Cardiovasc Pharmacol. 2017 Feb;69(2):93-100. doi: 10.1097/FJC.0000000000000446.

PMID:
27851698
17.

Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?

Mandras SA, Ventura HO, Corris PA.

Ochsner J. 2016 Fall;16(3):257-62. Review.

18.

Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.

Jain S, Khera R, Girotra S, Badesch D, Wang Z, Murad MH, Blevins A, Schmidt GA, Singh S, Gerke AK.

Chest. 2017 Jan;151(1):90-105. doi: 10.1016/j.chest.2016.08.1461. Epub 2016 Sep 9. Review.

PMID:
27615023
19.

Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies.

Fein DG, Zaidi AN, Sulica R.

J Clin Med. 2016 Aug 26;5(9). pii: E75. doi: 10.3390/jcm5090075. Review.

20.

Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.

Reis A, Twiss J, Vicente M, Gonçalves F, Carvalho L, Meireles J, Melo A, McKenna SP, Almeida L.

Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8.

Supplemental Content

Support Center